[1]柯万海 戴研 宁晓红.终末期患者心脏植入型电子器械的缓和医疗现状及临床管理[J].心血管病学进展,2020,(5):444-447.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.002]
　KE Wanhai,DAI Y an,NING X iaohong.Clinical Management and Palliative Care Status for End-stage Patients with Cardiovascular Implantable Electronic Devices[J].Advances in Cardiovascular Diseases,2020,(5):444-447.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.002]
点击复制

终末期患者心脏植入型电子器械的缓和医疗现状及临床管理()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年5期
页码:
444-447
栏目:
出版日期:
2020-05-25

文章信息/Info

Title:
Clinical Management and Palliative Care Status for End-stage Patients with Cardiovascular Implantable Electronic Devices
作者:
柯万海 戴研 宁晓红
(中国医学科学院　北京协和医学院　阜外医院 国家心血管病中心心血管疾病国家重点实验室）
Author(s):
KE Wanhai1; DAI Y an1; NING X iaohong 2
(1. Center of Arrhythmia, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China; 2. Palliative Care Group in Peking Union Medical College Hospital Peking Union Medical College, Chinese Academy of Medical Sciences,Beijing 100730, China)
关键词:
心脏植入型电子器械; 缓和医疗; 管理除颤仪
Keywords:
Cardiovascular implantable electronic devices; Palliative care; Management of implantable cardioverter defibrillator
DOI:
10.16806/j.cnki.issn.1004-3934.2020.05.002
摘要:
心脏植入型电子器械（CIED）包括起搏器、植入型心律转复除颤器（ICD）和心脏再同步化治疗（CRT）等。随着人口老龄化的增加及CIED植入适应证范围的逐渐扩大，CIED植入量逐年增加。但对于临床终末期患者，ICD或CRT联合ICD不但不能延长患者的生存期，反复的电除颤可能会给患者带来严重痛苦。临终患者CIED 的管理成为影响终末期患者生存质量的重要问题。 现就临终患者CIED的缓和医疗现状和临床管理决策中的影响因素以及临床处理策略展开综述。
Abstract:
Cardiovascular implantable electronic devices(CIED) include pacemaker,implantable cardioverter defibrillator(ICD) and cardiac resynchronization therapy(CRT).With the indications of CIED implantation expanding and the elderly population increasing, the number of CIED implantation is increasingly year by year.But for the end-stage patients, ICD or CRT combined with ICD can not prolong the survival period of patients, and repeated defibrillation may bring severe pain to patients.The management of CIED in terminal patients has become an important issue that affects the quality of life of end-stage patients. Therefore, this article reviews the issue about the palliative care status,the influencing factors in clinical management decision -making and clinical treatment strategies for the end-of-life patients with CIED

参考文献/References:

[1] Thylén I,Moser DK,Str?mberg A. Octo- and nonagenarians’outlook on life and death when living with an implantable cardioverter defibrillator:a cross-sectional study[J]. BMC Geriatr,2018,18(1):250.

[2] Stoevelaar R,Brinkman-Stoppelenburg A,Bhagwandien RE,et al. The incidence and impact of implantable cardioverter defibrillator shocks in the last phase of life:an integrated review[J]. Eur J Cardiovasc Nurs,2018,17(6):477-485.

[3] Steiner JM,Patton KK,Prutkin JM,et al. Moral distress at the end of a life:when family and clinicians do not agree on implantable cardioverter-defibrillator deactivation[J]. J Pain Symptom Manage,2018,55(2):530-534.

[4] Lampert R,Hayes DL,Annas GJ,et al. HRS expert consensus statement on the Management of Cardiovascular Implantable Electronic Devices(CIEDs) in patients nearing end of life or requesting withdrawal of therapy[J]. Heart Rhythm,2010,7(7):1008-1026.

[5] Padeletti L,Arnar DO,Boncinelli L,et al. EHRA expert consensus statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy[J]. Europace,2010,12(10):1480-1489.

[6] 曾治宇,林娜,张明东,等. 植入型心律转复除颤器一级预防的卫生经济学研究进展[J]. 心血管病学进展,2018,39(3):320-323.

[7] Kinch Westerdahl A,Sj?blom J,Mattiasson AC. Implantable cardioverter-defibrillator therapy before death:high risk for painful shocks at end of life[J]. Circulation,2014,129(4):422-429.

[8] McEvedy SM,Cameron J,Lugg E,et al. Implantable cardioverter defibrillator knowledge and end-of-life device deactivation:a cross-sectional survey[J]. Palliat Med,2018,32(1):156-163.

[9] Haugaa KH,Potpara TS,Boveda S,et al. Patients’ knowledge and attitudes regarding living with implantable electronic devices:results of a multicentre, multinational patient survey conducted by the European Heart Rhythm Association[J]. Europace,2018,20(2):386-391.

[10] Str?mberg A,Fluur C,Miller J,et al. ICD recipients’ understanding of ethical issues,ICD function, and practical consequences of withdrawing the ICD in the end-of life[J]. Pacing Clin Electrophysiol,2014,37(7):834-842.

[11] Dodson JA,Fried TR,van Ness PH,et al. Patient preferences for deactivation of implantable cardioverter-defibrillators[J]. JAMA Intern Med,2013,173(5):377-379.

[12] Lee MC,Sulmasy DP,Gallo J,et al. Decision-making of patients with implantable cardioverter-defibrillators at end of life:family members’ experiences[J]. Am J Hosp Palliat Care,2017,34(6):518-523.

[13] Fluur C,Bolse K,Str?mberg A,et al. Spouses’ reflections on implantable cardioverter defibrillator treatment with focus on the future and the end-of-life:a qualitative content analysis[J]. J Adv Nurs,2014,70(8):1758-1769.

[14] Buchhalter LC,Ottenberg AL,Webster TL,et al. Features and outcomes of patients who underwent cardiac device deactivation[J]. JAMA Intern Med,2014,174(1):80-85.

[15] Tajouri TH,Ottenberg AL,Hayes DL,et al. The use of advance directives among patients with implantable cardioverter defibrillators[J]. Pacing Clin Electrophysiol,2012,35(5):567-573.

[16] Butler K, Puri S. Deathbed shock:causes and cures[J]. JAMA Intern Med,2014,174(1):88-89.

[17] Kinch Westerdahl A,Frykman V. Physicians’ knowledge of implantable defibrillator treatment:are we good enough?[J]. Europace,2017,7(19):1163-1169.

[18] Rietjens JAC,Sudore RL,Connolly M,et al. Definition and recommendations for advance care planning:an international consensus supported by the European Association for Palliative Care[J]. Lancet Oncol,18(9): e543-e551.

[19] Sherazi S,Daubert JP,Block RC,et al. Physicians’ preferences and attitudes about end-of-life care in patients with an implantable cardioverter-defibrillator[J]. Mayo Clin Proc, 2008,83(10):1139-1141.

[20] Bradley A,Marks A. Clinician attitudes regarding ICD DEACTIVATion in DNR/DNI patients[J]. J Hosp Med,2017,12(7):498-502.

[21] Kusumoto FM, Schoenfeld MH, Barrett C,et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay：a report of the American College of Cardiology/American?Heart Association task force on clinical practice guidelines and the?Heart?Rhythm Society[J]. J Am Coll Cardiol ,2019,74(7): e51-e156.



[22] Pitcher D,Soar J,Hogg K,et al. Cardiovascular implanted electronic devices in people towards the end of life, during cardiopulmonary resuscitation and after death:guidance from the Resuscitation Council (UK), British Cardiovascular Society and National Council for Palliative Care[J]. Heart, 2016,102 Suppl 7:A1-A17.

[23] Hutchison K,Sparrow R. Ethics and the cardiac pacemaker:more than just end-of-life issues[J]. Europace,2018,20(5):739-746.

[24] Cappato R,Smith WM,Hood MA. Subcutaneous chronic implantable defibrillation systems in humans[J]. J Interv Card Electrophysiol,2012,34(3):325-332.

[25] Mueller PS,Hook CC, Hayes DL. Ethical analysis of withdrawal of pacemaker or implantable cardioverter-defibrillator support at the end of life[J]. Mayo Clin Proc,2003,78(8):959-963.

[26] Brady DR. Planning for deactivation of implantable cardioverter defibrillators at the end of life in patients with heart failure[J]. Crit Care Nurse,2016,36(6):24-31.

更新日期/Last Update: 2020-08-11